{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 10 of 92', 'CR845-CLIN3102', 'The number and reason(s) for missed dialysis as well as the use of', 'antipruritic medications, ESAs and iron will be recorded throughout', 'the Open-label Treatment Period.', 'The last dose of open-label study drug will be administered at the last', 'dialysis visit on Week 52, or Early Termination. A final safety', 'Follow-up Visit will be conducted 7-10 days after the', 'End-of-Treatment/Early Termination Visit.', 'STUDY DRUG', 'Study drug will be supplied in glass vials containing an extractable', 'volume of at least 1.3 mL of CR845 at a concentration of 0.05 mg/mL', 'in 0.04M isotonic acetate buffer, pH 4.5.', 'REFERENCE', 'Matching placebo (0.04M isotonic acetate buffer, pH 4.5) will be', 'PRODUCT', 'provided in glass vials containing an extractable volume of at least', '1.3 mL.', 'TREATMENT', 'Patients will be administered CR845 0.5 mcg/kg or placebo as a single', 'REGIMENS', 'IV bolus 3 times a week after each dialysis session for 12 weeks during', 'the Double-blind Treatment Period.', 'No study drug will be administered during the Discontinuation Period.', 'During the Open-label Treatment Period, patients will be administered', 'CR845 0.5 mcg/kg as a single IV bolus 3 times a week after each', 'dialysis session for up to 52 weeks.', 'STUDY DURATION', 'Double-blind Phase:', 'Screening Period: up to 4 weeks (may occur during Run-in Period at', 'the discretion of Investigator) inclusive of the 7-day Run-in Period', 'Double-blind Treatment Period: 12 weeks', 'Discontinuation Period: 2 weeks', 'Open-label Extension Phase:', 'Open-label Treatment Period: up to 52 weeks', 'Follow-up Period: 2 weeks', 'Total study duration for a single patient: up to approximately 72 weeks', 'STUDY', 'Efficacy Endpoints', 'ENDPOINTS', 'Primary Efficacy Endpoint', 'Proportion of patients achieving at least a 3-point improvement', 'from baseline with respect to the weekly mean of the daily 24-', 'hour Worst Itching Intensity NRS score at Week 12 of the', 'Double-blind Treatment Period', 'Secondary Efficacy Enppoints', 'Change from baseline in itch-related quality of life at the end', 'of Week 12 of the Double-blind Treatment Period, as assessed', 'by the 5-D Itch Scale total score', 'Change from baseline in itch-related quality of life at the end', 'of Week 12 of the Double-blind Treatment Period, as assessed', 'by the Skindex-10 Scale total score', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 12 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 11 of 92', 'CR845-CLIN3102', 'Proportion of patients achieving >4-point improvement from', 'baseline with respect to the weekly mean of the daily 24-hour', 'Worst Itching Intensity NRS at Week 12 of the Double-blind', 'Treatment Period.', 'Additional efficacy endpoints are described in Section 8.7.4.', 'Safety Endpoints', 'The safety endpoints used to evaluate the overall safety and tolerability', 'of CR845 will be adverse events, ECG, vital signs, and clinical safety', 'laboratory evaluations.', 'INTERIM', 'Safety data will be reviewed on an ongoing basis by the Sponsor and a', 'ASSESSMENT', 'Data Safety Monitoring Board (DSMB). The operation of the DSMB', '(Double-blind Phase)', \"will be governed by a charter that will describe the group's meeting\", 'frequency, procedures, and requirements for reporting its observations', 'to the Sponsor.', 'A single interim assessment for sample size re-estimation is planned', 'after approximately 50% of the first 350 randomized patients either', 'complete the 12-week Double-blind Treatment Period or discontinue', 'study drug prematurely. The interim assessment will be conducted by', 'an Independent Data Monitoring Committee (IDMC). Members of the', 'IDMC will not participate in the DSMB and will not be members of the', 'study team. During the interim assessment, the study team will remain', 'blinded to the data; however, the IDMC will receive unblinded', 'summary results to implement the decision rule for sample size re-', 'estimation. The IDMC will only communicate the decision to either', 'keep the original sample size or to increase it; no other results will be', 'provided to blinded staff. The DSMB will be made aware of the', 'decision, but not given the results that were the basis of the decision.', 'STATISTICAL', 'Analysis Populations', 'ANALYSIS', 'The Enrolled Population is defined as the group of patients who sign', 'informed consent.', 'The ITT Population is defined as the group of patients who are', 'randomized to a treatment group. The Double-blind Safety Population', 'is defined as the group of randomized patients who received at least', '1', 'dose of study drug during the Double-blind Treatment Period.', 'Following the intent-to-treat principle, patients in the ITT will be', 'analyzed according to their randomized treatment, regardless of the', 'actual treatment received. Patients in the Double-blind Safety Analysis', 'Population will be analyzed according to the actual treatment received.', 'The Double-blind Safety Population will be used to analyze all safety', 'endpoints collected during the Double-blind Phase, while the ITT', 'Population will be used to analyze all efficacy endpoints collected', 'during the Double-blind Phase.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 13 of 95']\n\n###\n\n", "completion": "END"}